A private-public deal will fund Merck&Co to produce, stockpile and attain approval for an Ebola vaccine that showed promising results last year, Nature and Science report. GAVI, a swiss organization that helps poor countries vaccinate children, announced yesterday at the World Economic Forum in Davos, Switzerland, that it will provide US $5 million to make this possible.
This vaccine is currently being used to vaccinate all known contacts of the recent Sierra Leone Ebola victim.
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in